Legislation Quick Search
02/22/2024 09:55 AM
Pennsylvania State Senate
https://www.legis.state.pa.us/cfdocs/Legis/CSM/showMemoPublic.cfm?chamber=S&SPick=20230&cosponId=38579
Share:
Home / Senate Co-Sponsorship Memoranda

Senate Co-Sponsorship Memoranda

Subscribe to PaLegis Notifications
NEW!

Subscribe to receive notifications of new Co-Sponsorship Memos circulated

By Member | By Date | Keyword Search


Senate of Pennsylvania
Session of 2023 - 2024 Regular Session

MEMORANDUM

Posted: December 12, 2022 04:36 PM
From: Senator Wayne Langerholc, Jr.
To: All Senate members
Subject: Court Assessments for Nonnarcotic Medication Substance Abuse Treatment Program
 
In the near future, I plan to re-introduce my legislation from last session, Senate Bill 449. This legislation will further address Pennsylvania’s ongoing opioid epidemic by better utilizing FDA-approved medication. Long-acting nonnarcotic, non-addictive medications have been used to successfully treat those with serious opioid addictions and have been shown to be effective at leading to full sobriety and independence from addiction.

My legislation would create the Court Assessments for Nonnarcotic Medication Substance Abuse Treatment Program. This will increase opportunities for courts to provide the long-acting nonnarcotic, non-addictive medication in conjunction with comprehensive substance abuse treatment programs.

The goal of the legislation is to better serve defendants who are addicted to opioids by providing a non-habit-forming treatment option. Utilizing long-acting, nonnarcotic, non-addictive medications have been shown to reduce a person’s need for treatment to around 6-12 months.

This bill will be a step in the right direction for increasing access to these treatment medications, and is another step in the multi-faceted approach to combating this horrific epidemic.

Previous co-sponsors to this legislation were:  Bartolotta, J.Ward, Stefano, K. Ward, and Yaw.

Please join me in co-sponsoring this important piece of legislation.



Introduced as SB253